Anorexia nervosa and Raynauds phenomenon: A case report

International Journal of Eating Disorders

Volumn 40, Issue 8, 2007, Pages 762-765

  Yucel, Basak ^a   Uzum, Ayse Kubat ^a   Ozbey, Nese ^a   Kamali, Sevil ^a   Yager, Joel ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Anorexia nervosa; Anorexia nervosa induced vasculopathy; Medical complications; Raynaud's phenomenon; Transdermal hormone replacement therapy

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; COLECALCIFEROL; ESTROGEN; NIFEDIPINE; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ADOLESCENT; AMENORRHEA; ANOREXIA NERVOSA; ARTICLE; BLOOD PRESSURE; BODY IMAGE; CASE REPORT; COLD EXPOSURE; CONNECTIVE TISSUE DISEASE; COUNSELING; DIET THERAPY; DISEASE ASSOCIATION; DISEASE DURATION; DOPPLER FLOWMETER; EATING DISORDER; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; OSTEOPENIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOTHERAPY; PULSE RATE; RAYNAUD PHENOMENON; TREATMENT OUTCOME; TREATMENT PLANNING; VASOSPASM; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION; ADULT; BONE DENSITY; DRUG EFFECT; FAMILY THERAPY; GROUP THERAPY; INTRADERMAL DRUG ADMINISTRATION; METABOLIC BONE DISEASE; MULTIMODALITY CANCER THERAPY;

ADMINISTRATION, CUTANEOUS; ADULT; AMENORRHEA; ANOREXIA NERVOSA; ASPIRIN; BONE DENSITY; BONE DISEASES, METABOLIC; CALCIUM CHANNEL BLOCKERS; COMBINED MODALITY THERAPY; COUNSELING; ESTROGEN REPLACEMENT THERAPY; FAMILY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; NIFEDIPINE; NUTRITION THERAPY; PLATELET AGGREGATION INHIBITORS; PSYCHOTHERAPY; PSYCHOTHERAPY, GROUP; RAYNAUD DISEASE;

EID: 36148956775     PISSN: 02763478     EISSN: 1098108X     Source Type: Journal    
DOI: 10.1002/eat.20418     Document Type: Article

References (17)

1. Comas JM, Archambeaud-Mouveroux F, Teissier MP, Hue MC, Laskar M. Acute ischemia of an arm manifesting Burger's disease. Predisposing role of anorexia nervosa. Rev Med Interne 1992;13:375-377.
2. De Zwaan M, Mitchell JE. Medical evaluation of the patient with an eating disorder: An overview. In: Mehler PS, Andersen AE, editors. Eating Disorders. Baltimore, MD: The Johns Hopkins University Press, 1999, pp. 44-62.
3. Launay D, Queyrel V, Hatron PY, Michon-Pasturel U, Hachulla E, Devulder B. Digital necrosis in a patient with anorexia nervosa. Association of vasculopathy and radial artery injury. Presse Med 2000;29:1850-1852.
4. Creager MA, Dzau VJ. Vascular diseases of the extremities. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, editors. Harrison's Principles of Internal Medicine, 16th ed. Philadelphia, PA: McGraw Hill, 2005, pp. 1489-1490.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.
6. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: A meta-analysis. Rheumatology (Oxford) 2005;44:145-150.
7. Rustin MHA, Foreman JC, Dowd PM. Anorexia nervosa associated with acromegaloid features, onset of acrocyanosis and Raynaud's phenomenon and worsening of chilblains. J R Soc Med 1990;83:495-496.
8. Bambery P, Malhotra S, Kaur U, Chadda R, Deodhar SD. Anorexia nervosa in a patients with systemic lupus erythematosus. Rheumatol Int 1987;7:177-179.
9. Golden NH, Lanzkowsky L, Schebendach J, Palestro CJ, Jacobson MS, Shenker IR. The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa. J Pediatr Adolesc Gynecol 2002;15:135-143.
10. Mehler PS. Osteoporosis in anorexia nervosa: Prevention and treatment. Int J Eat Disord 2003;33:113-126.
11. Jarrett PEM. Raynaud's disease and oral contraceptives. Br Med J 1976;2:699.
12. Lekakis J, Papamichael C, Mavrikakis M, Voutsas A, Stamatelopoulos S, Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud phenomenon secondary to systemic sclerosis. Am J Cardiol 1998;82:1555-1557.
13. Julkunen HA. Oral contraceptives in systemic lupus erythematosis: Side effects and influence on the activity of SLE. Scand J Rehumatol 1991;20:427-433.
14. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med 2005;142:953-962.
15. Sibilia J. Treatment of systemic lupus erythematosus in 2006. Joint Bone Spine 2006;73:591-598.
16. Al-Allaf A, Belch JJF. Raynaud's phenomenon. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. Philadelphia, PA: Elsevier, 2003, pp. 1507-1512.
17. Eilertsen AL, Hoibraaten E, Os I, Andersen TO, Sandvik L, Sandset PM. The effects of oral and transdermal hormone replacement therapy on CRP levels and other inflammatory markers in women with high risk of thrombosis. Maturitas 2005;52:111-118.